All News
Why I love the late breaking abstracts
Every year I love the late breaking abstracts. It’s consistently my favourite part of the meeting program, by some distance. Here's why you should love them, too.
Read Article
IL-23 Blockade Goes Oral
A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies.
Read Article
Rheumatoid arthritis and the ‘big bang’ at #ACR25!
Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA?
https://t.co/QDvdiP3q9R https://t.co/cz4j4vZkSd
Dr. John Cush RheumNow ( View Tweet)
AI Scribes Found their Favorite Doctors
Dr. Aurelie Najm discusses abstract 0189, "“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists", presented at #ACR25
https://t.co/QTYFvLa95Y https://t.co/ZIvMovloBL
Dr. John Cush RheumNow ( View Tweet)
Rheum Now Rheumatology Round-Up — LIVE
Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25.
📡 Live https://t.co/ZwP4UwojuZ
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Imaging
Dr. Arthur Kavanaugh talks about imaging in psoriatic arthritis at #ACR25
https://t.co/l6MKTgEJXu https://t.co/sKhoQWCPli
Dr. John Cush RheumNow ( View Tweet)
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE
Dr. Sheila Reyes reports on the scientific session presentation of the #ACR25 treatment guidelines for SLE
https://t.co/Bh1fSFf8ju https://t.co/OH8h9GDeMf
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Day 1 Recap: #ACR25 Highlights
Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope, and Jack Cush for Day 1 highlights from the 2025 ACR Convergence in Chicago, focusing on abstracts/sessions: 0775, SLE guidelines, 0163, 0832, 0776, 0792, and 0164. https://t.co/ODte4XY82a
Dr. John Cush RheumNow ( View Tweet)
Why are vaccine Abs maintained after CAR-T
-depletion of pathogenic #Abs are dampened/eliminated
Clonal repetoire expansion
Remission=naive B cell pop'n
Reset immune system sparing memory cells
vs ?not all pathogenic cells eliminated in tissue
#ACR25 @RheumNow @ACRheum
#26S21 https://t.co/jb3dD5Ssip
Janet Pope Janetbirdope ( View Tweet)
Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x
Great discussion by @EBRheum @AkhilSoodMD @Dr_Brian_MD .
I have always been a FK fan in lupus nephritis as an add on therapy , the only inconvenience is regular monitoring.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
From Fitbit to first diagnosis: AI is rewriting the RA playbook
Two studies presented at this year’s #ACR25 meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden. https://t.co/8AwBZkyZIW
Dr. John Cush RheumNow ( View Tweet)
Day 1 Recap: #ACR25 Highlights
Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they discuss highlights and key takeaways from the Day 1 Recap on Sunday, October 26th.
https://t.co/Kq8TDBLUYZ https://t.co/TNM8ZAji9w
Dr. John Cush RheumNow ( View Tweet)
What does the FDA regulatory approach look like for CAR-T and T cell engages right now?
The FDA session at #ACR25 gave some clues @RheumNow https://t.co/wHNnNTrXaE
Links:
David Liew drdavidliew ( View Tweet)
#ACR25 Please find my blog on update and progress of clinical trials in #Sjogren #SjD @RheumNow
https://t.co/u8pxZ5FeBX https://t.co/KAnRo3Zqnz
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
CAR-T vs bispecific antibodies - what's the difference?
@andrew02114 @MGHCancerCenter with the heme-onc point of view in the #ACR25 BCRC @RheumNow https://t.co/7KJCfiQKWM
Links:
David Liew drdavidliew ( View Tweet)
Rheum Now Rheumatology Round-Up — LIVE
Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25.
📡 Live https://t.co/G6jKiHYVoR
Dr. John Cush RheumNow ( View Tweet)
#MTX is NOT the same as TCZ in #GCA in RCT
#TCZ did better
So use an advanced Rx for GCA
ex TCZ, Upa when approved
METOGiA RCT - more relapses in MTX
abst#891 #ACR25 @ACRheum @RheumNow https://t.co/wsEKGF8dW2
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Next Generation T-Cell Engager: The Future
Dr. Alfred Kim reviews abstract 0001 presented at #ACR25.
https://t.co/vmZYfmKCm8 https://t.co/PkLOs9lZ8l
Links:
Dr. John Cush RheumNow ( View Tweet)
